Amanda Williams
Family · Kansas City, KSNPI 1134639669
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,939 of the $20,157 with a category attached, or 79.1%. Sanofi-aventis U.S. LLC accounts for 85.6% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $7,637, more than ten times the $398 reported in 2021. Among family clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 157 payments — averaging $128.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$17K
- Dexcom, Inc.$1K
- Tandem Diabetes Care, Inc.$326
- Lilly USA, LLC$278
- Medtronic$261
- Mannkind Corporation$209
- plus $716 from 9 others
What the payments were for
- Speaking & faculty fees$15,93979%
- Travel & lodging$1231%
- Food & beverage$3,99920%
- Education$970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 51 | $17,259 |
| Dexcom, Inc. | 33 | $1,109 |
| Tandem Diabetes Care, Inc. | 9 | $326 |
| Lilly USA, LLC | 14 | $278 |
| Medtronic | 6 | $261 |
| Mannkind Corporation | 9 | $209 |
| Insulet Corporation | 8 | $168 |
| Abbott | 7 | $130 |
| Xeris Pharmaceuticals, Inc. | 6 | $112 |
| Sequel Med Tech, LLC | 4 | $103 |
| Boehringer Ingelheim | 3 | $61 |
| BETA Bionics, Inc. | 2 | $50 |
| Ascendis Pharma Endocrinology Inc | 2 | $39 |
| Novo Nordisk | 2 | $33 |
| Ascensia Diabetes Care US Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TZIELD$14,563
- MINIMED 780G$170
- DEXCOM G7 GSS (161)$149
- t:slim X2 Insulin Pump with Control-IQ$121
How this compares
$20,157 in reported general payments places this provider in the 95th percentile of 1,579 family providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 325 | $443,425 |
| MounjaroTirzepatide | 318 | $435,337 |
| JardianceEmpagliflozin | 285 | $333,332 |
| TrulicityDulaglutide | 81 | $116,159 |
| Tresiba Flextouch U-200Insulin Degludec | 93 | $107,670 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 75 | $65,850 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 33 | $51,638 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 23 | $35,634 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 36 | $35,509 |
| Humalog Kwikpen U-100Insulin Lispro | 76 | $20,226 |
| FarxigaDapagliflozin Propanediol | 16 | $19,319 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $19,155 |
| Novolog FlexpenInsulin Aspart | 60 | $16,328 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $15,945 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 26 | $12,239 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $278 | $554,547414 claims |
| Novo NordiskOzempic, Novolog | $33 | $453,185353 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $61 | $368,841321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,579 family providers in Kansas.
Other family in Kansas City
- Zohra HussainiKansas City$329K
- Adam CaseKansas City$34K
- Kristina DelaneyKansas City$27K
- Mindy EldridgeKansas City$12K
- Liza RodriguezKansas City$11K
- Jhunne GalimbaKansas City$6K
- Graceann SandriKansas City$6K
- Jennifer ChesterOverland Park$327K
- Amanda CaldwellLeawood$203K
- Kayla del RioWichita$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.